ViceBio Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
23
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.6B
ViceBio General Information
Description
Developer of innovative vaccines designed for respiratory viral infections. The company develops the patented molecular clamp technology that stabilizes viral glycoproteins in prefusion conformation to deliver protective, ready-to-use, fully liquid vaccines, enabling long-term storage and convenient administration of respiratory viruses, including respiratory syncytial virus, metapneumovirus, influenza, and SARS-CoV-2.
Contact Information
Website
www.vicebio.comCorporate Office
- 168 Shoreditch High Street
- 2nd Floor
- London E1 6RA
- England, United Kingdom
Corporate Office
- 168 Shoreditch High Street
- 2nd Floor
- London E1 6RA
- England, United Kingdom
ViceBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 04-Dec-2025 | $1.6B | Completed | Clinical Trials - Phase 1 | ||
| 3. Later Stage VC (Series B) | 23-Sep-2024 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 21-Jul-2022 | $18M | $18M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC | 13-Apr-2021 | Completed | Clinical Trials - Phase 1 |
ViceBio Patents
ViceBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026033492-A1 | Chimeric fusion proteins as human metapneumovirus (hmpv) vaccines | Pending | 08-Aug-2024 | ||
| WO-2026033489-A1 | Chimeric fusion proteins as respiratory syncytial virus (rsv) vaccines | Pending | 08-Aug-2024 | ||
| AU-2023242948-A1 | Improved chimeric polypeptides and uses thereof | Pending | 31-Mar-2022 | ||
| EP-4499668-A1 | Improved chimeric polypeptides and uses thereof | Pending | 31-Mar-2022 | ||
| EP-4499668-A4 | Improved chimeric polypeptides and uses thereof | Pending | 31-Mar-2022 | C07K14/005 |
ViceBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ViceBio Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avoro Capital | Venture Capital | Minority | ||
| Medicxi Ventures (UK) | Venture Capital | Minority | ||
| TCG Crossover Management | Venture Capital | Minority | ||
| The Goldman Sachs Group | Investment Bank | Minority | ||
| UniQuest Extension Fund | Venture Capital | Minority |
ViceBio FAQs
-
When was ViceBio founded?
ViceBio was founded in 2018.
-
Where is ViceBio headquartered?
ViceBio is headquartered in London, United Kingdom.
-
What is the size of ViceBio?
ViceBio has 23 total employees.
-
What industry is ViceBio in?
ViceBio’s primary industry is Drug Discovery.
-
Is ViceBio a private or public company?
ViceBio is a Private company.
-
What is the current valuation of ViceBio?
The current valuation of ViceBio is .
-
What is ViceBio’s current revenue?
The current revenue for ViceBio is .
-
How much funding has ViceBio raised over time?
ViceBio has raised $118M.
-
Who are ViceBio’s investors?
Avoro Capital, Medicxi Ventures (UK), TCG Crossover Management, The Goldman Sachs Group, and UniQuest Extension Fund are 5 of 6 investors who have invested in ViceBio.
-
When was ViceBio acquired?
ViceBio was acquired on 04-Dec-2025.
-
Who acquired ViceBio?
ViceBio was acquired by Sanofi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
